BookmarkSubscribeRSS Feed
Minhtrang
Obsidian | Level 7

Hi,

Could anyone show me how to calculate sample size for a non-inferiority clinical trial with given information as following?

"The primary hypothesis aims to show non-inferiority on 3P-MACE for empagliflozin versus placebo based on a non-inferiority margin of < 1.3 (upper limit of the adjusted 95% confidence interval (CI)) for the hazard ratio. The upper limit of the adjusted 95% CI for the HR of <1.3 was based on FDA guidance for CV trials evaluating new anti-hyperglycemic therapies for T2DM [9]. Patients who receive either 10 mg or 25 mg of empagliflozin will be pooled into a common treatment group for the purposes of the primary analysis. A 4-step hierarchical testing strategy will be followed: 1) non-inferiority test of the primary outcome (3P-MACE), 2) non-inferiority test of the key secondary outcome (4P-MACE), 3) superiority test of the primary outcome (3P-MACE) and 4) superiority test of the key secondary outcome (4P-MACE). A minimum of 691 confirmed primary outcome events are required to provide 90% power with a one-sided α level of 0.025, assuming equal risk between the placebo and empagliflozin groups. With a minimum of 691 events, the trial will also have at least 80% power to detect a hazard ratio of 0.785 (corresponding to a 21.5% risk reduction in CV outcome events) for the primary outcome."

 

So actually how to get the number of 691 as stated in the article?

 

Thanks a lot for your kinda help.

Trang 

 

SAS Innovate 2025: Call for Content

Are you ready for the spotlight? We're accepting content ideas for SAS Innovate 2025 to be held May 6-9 in Orlando, FL. The call is open until September 25. Read more here about why you should contribute and what is in it for you!

Submit your idea!

What is ANOVA?

ANOVA, or Analysis Of Variance, is used to compare the averages or means of two or more populations to better understand how they differ. Watch this tutorial for more.

Find more tutorials on the SAS Users YouTube channel.

Discussion stats
  • 0 replies
  • 627 views
  • 0 likes
  • 1 in conversation